OLMA 241220 2.50P (OLMA241220P2500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Dec 2 09:30 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

14 hours ago

Update

$Olema Pharmaceuticals (OLMA.US)$ Reuters· 3 mins ago
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement

Trytosaveabit

Nov 30 10:33

Eyes on! TB on hourly! Plus data release coming could help bring volume to help push this bullish formation!

$Olema Pharmaceuticals (OLMA.US)$ Olema Oncology to Present New Data Combining Palazestrant With Ribociclib at the San Antonio Breast Cancer Symposium
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024
Poster Details
Title:A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal gr...

Moomoo AI

Nov 25, 2023 06:49

Although the sale doesn't necessarily signify a negative view on the company's future, absence of insider buying could induce concerns. Other company risks should be considered when investing.

President Sean Bohen Sold A Bunch Of Shares In Olema Pharmaceuticals

Moomoo AI

Oct 17, 2023 06:06

Mr. Garland's expertise in biopharma is predicted to boost late-stage development of Olema's lead product. This could solidify the company's influence in shaping next-gen therapies for women's cancers.

Press Release: Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

Weight-loss drugmakers report strong earnings: Boon or bane?

Trytosaveabit

Oct 12, 2023 06:17

NEWS!

$Olema Pharmaceuticals (OLMA.US)$ Olema Pharmaceuticals Announced New Preclinical Data Regarding The Discovery Of Novel Compounds Targeting KAT6, An Epigenetic Target That Is Dysregulated In Breast And Other Cancers